Machine learning & deep learning tools in pharmaceutical sciences: A comprehensive review

Abstract

Drug discovery and development is an important area of research for pharmaceutical industries and medicinal chemists. This classical approach demanded significant investments of time and resources to bring a single drug to market. Furthermore, the complexity and vast scale of data from genomics, proteomics, microarrays, and clinical trials present significant challenges in the drug discovery pipeline. Nevertheless, bioinformatics, pharmacoinformatics, and cheminformatics technologies have been developed thanks to breakthroughs in computational methodologies and a surge in multi-omics data, drastically shortening the time it takes to create new drugs. Large amounts of biological data stored in global databases are the building blocks for machine learning and deep learning methods. They make it easier to find patterns and models that can help find therapeutically active molecules with less time, work, and money. Machine learning and deep learning technology are vital in drug design and development. We have applied these algorithms to various drug discovery processes such as protein structure prediction, toxicity prediction, oral bioavailability prediction, de novo design of new chemical scaffolds, structure-based and ligand-based virtual screening, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, and clinical trial design. Historical evidence underscores the successful implementation of AI and deep learning in this domain. Finally, we highlight some successful machine learning or deep learning-based models employed in the drug design and development pipeline. Furthermore, there has been a notable increase in interest regarding the application of AI technology in hospital pharmacy settings, which has been discussed in this review. This review will be invaluable to medicinal and computational chemists seeking DL tools for drug discovery projects and hospital pharmacies.

Keywords

Artificial intelligence / Machine learning / Deep learning / Drug discovery / Virtual screening / Artificial neural networks / Hospital pharmacy

References

[1] Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2012 Mar; 24 (3): 773- 780.

[2] Das S, Dey R, Nayak AK. Artificial intelligence in pharmacy. IJPER. 2021 May 17; 55 (2): 304- 318.

[3] Russell S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence: an open letter. AI Mag. 2015; 36 (4).

[4] Dasta JF. Application of artificial intelligence to pharmacy and medicine. Hosp Pharm. 1992 Apr;27(4):312, 5, 319-322. PMID: 10183640.

[5] Smietana K, Siatkowski M, Møller M. Trends in clinical success rates. Nat Rev Drug Discov. 2016 Jun; 15 (6): 379- 380.

[6] Mullard A. FDA drug approvals. Nat Rev Drug Discov. 2018; 18 (2): 85- 89, 2019 Feb.

[7] Hopfinger AJ. Computer-assisted drug design. J Med Chem. 1985 Sep; 28 (9): 1133- 1139.

[8] Martin YC. [29] Computer-assisted rational drug design. Methods Enzymol. 1991 Jan 1; 203: 587- 613.

[9] Yu W, MacKerell AD. Computer-aided drug design methods. Antibiotics: Methods and Protocols. 2017: 85- 106.

[10] Hassan Baig M, Ahmad K, Roy S, et al. Computer aided drug design: success and limitations. Curr Pharmaceut Des. 2016 Feb 1; 22 (5): 572- 581.

[11] Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem Rev. 2019 Sep 25; 119 (18): 10520- 10594.

[12] Khan T, Ahmad MM, Munir MU, Bukhari SN, Naveed MA. Prospects of artificial intelligence in the improvement of healthcare professions: a review. J Pharm (Lahore). 2024 Jan 31; 4 (1): 129- 137.

[13] Schneider P, Schneider G. De novo design at the edge of chaos: Miniperspective. J Med Chem. 2016 May 12; 59 (9): 4077- 4086.

[14] Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. Drug Discov Today. 2015 Mar 1; 20 (3): 318- 331.

[15] Parry DM. Closing the loop: developing an integrated design, make, and test platform for discovery. ACS Med Chem Lett. 2019 May 15; 10 (6): 848- 856.

[16] Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020 Feb 20; 180 (4): 688- 702.

[17] Viceconti M, Henney A, Morley-Fletcher E. In silico clinical trials: how computer simulation will transform the biomedical industry. International Journal of Clinical Trials. 2016 3 (2): 37- 46.

[18] Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends in pharmacological sciences. 2019 Aug 1; 40 (8): 577- 591.

[19] Nettekoven M, Thomas AW. Accelerating drug discovery by integrative implementation of laboratory automation in the workflow. Curr Med Chem. 2002 Dec 1; 9 (23): 2179- 2190.

[20] Selekman JA, Qiu J, Tran K, et al. High-throughput automation in chemical process development. Annu Rev Chem Biomol Eng. 2017 Jun 7; 8 (1): 525- 547.

[21] Manikiran SS, Prasanthi NL. Artificial intelligence: milestones and role in pharma and healthcare sector. Pharma times. 2019; 51: 9- 56.

[22] Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibioticresistant superbugs. ACS Chem Biol. 2009 Jan 16; 4 (1): 65- 74.

[23] Agatonovic-Kustrin S, Beresford R, et al. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharmaceut Biomed Anal. 2000 Jun 1; 22 (5): 717- 727.

[24] Haykin S. Neural Networks: A Comprehensive Foundation. Prentice Hall PTR; 1998Jul 1;

[25] Gasteiger J, Li X, Simon V, Novič M, Zupan J, et al. Neural nets for mass and vibrational spectra. J Pharmaceut Biomed Anal. 1993 Mar 1; 292: 141- 159.

[26] Achanta AS, Kowalski JG, Rhodes CT, et al. Artificial neural networks: implications for pharmaceutical sciences. Drug Dev Ind Pharm. 1995 Jan 1; 21 (1): 119- 155.

[27] Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. Expet Opin Drug Metabol Toxicol. 2009 Feb 1; 5 (2): 149- 169.

[28] Sutariya V, Groshev A, Sadana P, Bhatia D, Pathak Y. Artificial neural network in drug delivery and pharmaceutical research. Open Bioinf J. 2013 Dec 13; 7 (1).

[29] Gutiérrez PA, Hervás-Martínez C. Hybrid artificial neural networks: models, algorithms and data. InInternational Work-Conference on Artificial Neural Networks 2011 Jun vol. 8 (pp. 177-184). Berlin, Heidelberg: Springer Berlin Heidelberg.

[30] Taskinen J, Yliruusi J. Prediction of physicochemical properties based on neural network modelling. Adv Drug Deliv Rev. 2003 Sep 12; 55 (9): 1163- 1183.

[31] Fleming N. How artificial intelligence is changing drug discovery. Nature. 2018 May 1; 557 (7706): S55.

[32] Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev. 2003 Sep 12; 55 (9): 1201- 1215.

[33] Elbadawi M, Gaisford S, Basit AW. Advanced machine-learning techniques in drug discovery. Drug Discov Today. 2021 Mar 1; 26 (3): 769- 777.

[34] Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine learning in drug discovery: a review. Artif Intell Rev. 2022 Mar; 55 (3): 1947- 1999.

[35] Toh TS, Dondelinger F, Wang D. Looking beyond the hype: applied AI and machine learning in translational medicine. EBioMedicine. 2019 Sep 1; 47: 607- 615.

[36] Osisanwo FY, Akinsola JE, Awodele O, Hinmikaiye JO, Olakanmi O, Akinjobi J. Supervised machine learning algorithms: classification and comparison. Int J Comput Trends Technol. 2017 Jun; 48 (3): 128- 138.

[37] Zhang HH. Supervised Learning. Wiley: Wiley StatsRef: Statistics Reference Online; 2014 Apr 14; 1- 7.

[38] Larranaga P, Calvo B, Santana R, et al. Machine learning in bioinformatics. Briefings Bioinf. 2006 Mar; 7 (1): 86- 112.

[39] Aumentado-Armstrong TT, Istrate B, Murgita RA. Algorithmic approaches to protein-protein interaction site prediction. Algorithm Mol Biol. 2015 Dec; 10: 1- 21.

[40] Kotsiantis SB, Zaharakis I, Pintelas P. Supervised machine learning: a review of classification techniques. Emerging artificial intelligence applications in computer engineering. 2007 Jun 10; 160 (1): 3- 24.

[41] Parasa NA, Namgiri JV, Mohanty SN, Dash JK. Introduction to unsupervised learning in bioinformatics. Data Analytics in Bioinformatics: A Machine Learning Perspective. 2021 Feb 1: 35- 49.

[42] Tavallali P, Tavallali P, Singhal M. K-means tree: an optimal clustering tree for unsupervised learning. J Supercomput. 2021 May; 77 (5): 5239- 5266.

[43] Brydges R, Dubrowski A, Regehr G. A new concept of unsupervised learning: directed self-guided learning in the health professions. Acad Med. 2010 Oct 1; 85 (10): S49- S55.

[44] Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013 Apr; 9 (4): 232- 240.

[45] K Singh R, Lee JK, Selvaraj C, et al. Protein engineering approaches in the postgenomic era. Curr Protein Pept Sci. 2018 Jan 1; 19 (1): 5- 15.

[46] Lima AN, Philot EA, Trossini GH, Scott LP, Maltarollo VG, Honorio KM. Use of machine learning approaches for novel drug discovery. Expet Opin Drug Discov. 2016 Mar 3; 11 (3): 225- 239.

[47] Costa PR, Acencio ML, Lemke N. A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. InBMC genomics. BioMed Central. 2010 Dec; 11: 1- 15.

[48] Volk MJ, Lourentzou I, Mishra S, Vo LT, Zhai C, Zhao H. Biosystems design by machine learning. ACS Synth Biol. 2020 Jun 2; 9 (7): 1514- 1533.

[49] Jeon J, Nim S, Teyra J, et al. A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med. 2014 Dec; 6: 1- 8.

[50] Mamoshina P, Volosnikova M, Ozerov IV, et al. Machine learning on human muscle transcriptomic data for biomarker discovery and tissue-specific drug target identification. Front Genet. 2018 Jul 12; 9: 242.

[51] Lonsdale J, Thomas J, Salvatore M, et al. The genotype-tissue expression (GTEx) project. Nat Genet. 2013 Jun; 45 (6): 580- 585.

[52] Sharma K, Patidar K, Ali MA, et al. Structure-based virtual screening for the identification of high affinity compounds as potent VEGFR2 inhibitors for the treatment of renal cell carcinoma. Current topics in medicinal chemistry. 2018 Oct 1; 18 (25): 2174- 2185.

[53] Patidar K, Deshmukh A, Bandaru S, et al. Virtual screening approaches in identification of bioactive compounds Akin to delphinidin as potential HER2 inhibitors for the treatment of breast cancer. Asian Pac J Cancer Prev APJCP. 2016 Apr 1; 17 (4): 2291- 2295.

[54] Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev. 2014 Jan 1; 66 (1): 334- 395.

[55] Reddy KK, Singh SK. Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors. Chem Biol Interact. 2014 Jul 25; 218: 71- 81.

[56] Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinf Biol Insights. 2020 Jan; 14: 1177932219899051.

[57] Cova TF, Pais AA. Deep learning for deep chemistry: optimizing the prediction of chemical patterns. Frontiers in chemistry. 2019 Nov 26; 7: 809.

[58] Brereton RG. Self organising maps for visualising and modelling. Chem Cent J. 2012 May 2; 6 (Suppl 2): S1.

[59] Cherkasov A, Muratov EN, Fourches D, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014 Jun 26; 57 (12): 4977- 5010.

[60] Palyulin VA, Radchenko EV, Zefirov NS. Molecular field topology analysis method in QSAR studies of organic compounds. J Chem Inf Comput Sci. 2000; 40: 659- 667.

[61] Mouchlis VD, Afantitis A, Serra A, et al. Advances in de novo drug design: from conventional to machine learning methods. Int J Mol Sci. 2021 Feb 7; 22 (4): 1676.

[62] LeCun Y, Bengio Y, Hinton G, et al. Deep learning. nature. 2015 May 28; 521 (7553): 436- 444.

[63] Min S, Lee B, Yoon S. Deep learning in bioinformatics. Briefings Bioinf. 2017 Sep 1; 18 (5): 851- 869, 1.

[64] Ongsulee P. Artificial intelligence, machine learning and deep learning. In: 2017 15th International Conference on ICT and Knowledge Engineering (ICT&KE). Bangkok, Thailand: IEEE; 2017 1- 6.

[65] Kumar D, Gupta AK, Chandna P, Pal M. Optimization of neural network parameters using Grey-Taguchi methodology for manufacturing process applications. Proc IME C J Mech Eng Sci. 2015 Oct; 229 (14): 2651- 2664.

[66] Jing Y, Bian Y, Hu Z, Wang L, Xie XQ. Deep learning for drug design: an artificial intelligence paradigm for drug discovery in the big data era. AAPS J. 2018; 20 (3): 58.

[67] Abiodun OI, Jantan A, Omolara AE, Dada KV, Mohamed NA, Arshad H. State-of-theart in artificial neural network applications: a survey. Helyon. 2018 Nov 1; 4 (11).

[68] Luo Y, Zhao X, Zhou J, et al. A network integration approach for drug-target interaction prediction and computational drug repositioning from heterogeneous information. Nat Commun. 2017 Sep 18; 8 (1): 573.

[69] Chen R, Liu X, Jin S, Lin J, Liu J, et al. Machine learning for drug-target interaction prediction. Molecules. 2018 Aug 31; 23 (9): 2208.

[70] Peng J, Li J, Shang X, et al. A learning-based method for drug-target interaction prediction based on feature representation learning and deep neural network. BMC Bioinf. 2020 Sep 17; 21 (Suppl 13): 394.

[71] Li Y, Qiao G, Wang K, Wang G. Drug-target interaction predication via multichannel graph neural networks. Briefings Bioinf. 2022 Jan; 23 (1): bbab346.

[72] Ding Y, Tang J, Guo F. Identification of drug-target interactions via multi-view graph regularized link propagation model. Neurocomputing. 2021 Oct 21; 461: 618- 631.

[73] Rayhan F, Ahmed S, Mousavian Z, Farid DM, Shatabda S. FRnet-DTI: deep convolutional neural network for drug-target interaction prediction. Helyon. 2020 Mar 1; 6 (3).

[74] Rayhan F, Ahmed S, Mousavian Z, Farid DM, Shatabda S. FRnet-DTI: convolutional neural networks for drug-target interaction. arXiv preprint arXiv:1806.07174. Helyon. 2018 Jun; 7.

[75] Wan F, Zhu Y, Hu H, et al. DeepCPI: a deep learning-based framework for largescale in silico drug screening. Dev Reprod Biol. 2019 Oct; 17 (5): 478- 495.

[76] Ijzerman AP, Guo D. Drug-target association kinetics in drug discovery. Trends Biochem Sci. 2019 Oct 1; 44 (10): 861- 871.

[77] Öztürk H, Özgür A, Ozkirimli E. DeepDTA: deep drug-target binding affinity prediction. Bioinformatics. 2018 Sep 1; 34 (34): i821- i829.

[78] Guo Y, Li W, Wang B, Liu H, Zhou D. DeepACLSTM: deep asymmetric convolutional long short-term memory neural models for protein secondary structure prediction. BMC Bioinf. 2019 Dec; 20: 1- 2.

[79] Öztürk H, Ozkirimli E, Özgür A. WideDTA: prediction of drug-target binding affinity. arXiv preprint arXiv:1902.04166. 2019 Feb 4.

[80] Thafar M, Raies AB, Albaradei S, Essack M, Bajic VB. Comparison study of computational prediction tools for drug-target binding affinities. Frontiers in chemistry. 2019 Nov 20; 7: 782.

[81] Feng Q, Dueva E, Cherkasov A, Ester M. Padme: a deep learning-based framework for drug-target interaction prediction. arXiv preprint arXiv:1807.09741. 2018 Jul 25.

[82] Karimi M, Wu D, Wang Z, Shen Y, Zhou D. DeepAffinity: interpretable deep learning of compound-protein affinity through unified recurrent and convolutional neural networks. Bioinformatics. 2019 Sep 15; 35 (18): 3329- 3338.

[83] Morris GM, Lim-Wilby M. Molecular docking. Molecular Modeling of Proteins. 2008: 365- 382.

[84] Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011 Jun 1; 7 (2): 146- 157.

[85] Gao K, Nguyen DD, Sresht V, Mathiowetz AM, Tu M, Wei GW. Are 2D fingerprints still valuable for drug discovery? Phys Chem Chem Phys. 2020; 22 (16): 8373- 8390.

[86] Pereira JC, Caffarena ER, Dos Santos CN. Boosting docking-based virtual screening with deep learning. J Chem Inf Model. 2016 Dec 27; 56 (12): 2495- 2506.

[87] Gentile F, Agrawal V, Hsing M, et al. Deep docking: a deep learning platform for augmentation of structure-based drug discovery. ACS Cent Sci. 2020 May 19; 6 (6): 939- 949.

[88] Ding X, Zhang B. DeepBAR: a fast and exact method for binding free energy computation. The journal of physical chemistry letters. 2021 Mar 15; 12 (10): 2509- 2515.

[89] Zhang L, Tan J, Han D, Zhu H, et al. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov Today. 2017 Nov 1; 22 (11): 1680- 1685.

[90] Batool M, Ahmad B, Choi S, et al. A structure-based drug discovery paradigm. Int J Mol Sci. 2019 Jun 6; 20 (11): 2783.

[91] Wei GW. Protein structure prediction beyond AlphaFold. Nat Mach Intell. 2019 Aug; 1 (8): 336- 337.

[92] Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. nature. 2021 Aug; 596 (7873): 583- 589.

[93] Ruff KM, Pappu RV, et al. AlphaFold and implications for intrinsically disordered proteins. Journal of molecular biology. 2021 Oct 1; 433 (20): 167208.

[94] Kinch LN, Pei J, Kryshtafovych A, Schaeffer RD, Grishin NV. Topology evaluation of models for difficult targets in the 14th round of the critical assessment of protein structure prediction (CASP14). Proteins: Struct, Funct, Bioinf. 2021 Dec; 89 (12): 1673- 1686.

[95] Deng H, Jia Y, Zhang Y. Protein structure prediction. Int J Mod Phys B. 2018 Jul 20; 32 (18): 1840009.

[96] Kryshtafovych A, Schwede T, Topf M, Fidelis K, Moult J. Critical assessment of methods of protein structure prediction (CASP)—round XIII. Proteins: Struct, Funct, Bioinf. 2019 Dec; 87 (12): 1011- 1020.

[97] Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov. 2005 Aug; 4 (8): 649- 663.

[98] Olivecrona M, Blaschke T, Engkvist O, Chen H. Molecular de-novo design through deep reinforcement learning. J Cheminf. 2017 Dec; 9: 1, 4. 1.

[99] Zhou Z, Kearnes S, Li L, Zare RN, Riley P. Optimization of molecules via deep reinforcement learning. Sci Rep. 2019 Jul 24; 9 (1): 10752.

[100] Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Sci Adv. 2018 Jul 25; 4 (7): eaap7885.

[101] Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol. 2020 Feb; 38 (2): 143- 145.

[102] Vanhaelen Q, Lin YC, Zhavoronkov A. The advent of generative chemistry. ACS Med Chem Lett. 2020 Jul 14; 11 (8): 1496- 1505.

[103] Lai J, Li X, Wang Y, Yin S, Zhou J, Liu Z. AIScaffold: a web-based tool for scaffold diversification using deep learning. J Chem Inf Model. 2020 Dec 28; 61 (1): 1- 6.

[104] Maragakis P, Nisonoff H, Cole B, Shaw DE. A deep-learning view of chemical space designed to facilitate drug discovery. J Chem Inf Model. 2020 Jul 22; 60 (10): 4487- 4496.

[105] Lionta E, Spyrou G, K Vassilatis D, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current topics in medicinal chemistry. 2014 Aug 1; 14 (16): 1923- 1938.

[106] Li Q, Shah Shah. Structure-based virtual screening. Protein bioinformatics: from protein modifications and networks to. Proteomics. 2017: 111- 124.

[107] Ripphausen P, Nisius B, Bajorath J. State-of-the-art in ligand-based virtual screening. Drug Discov Today. 2011 May 1; 16 (9-10): 372- 376.

[108] Chen B, Harrison RF, Papadatos G, et al. Evaluation of machine-learning methods for ligand-based virtual screening. J Comput Aided Mol Des. 2007 Jan; 21: 53- 62.

[109] Wu D, Huang Q, Zhang Y, et al. Screening of selective histone deacetylase inhibitors by proteochemometric modeling. BMC Bioinf. 2012 Dec; 13: 1, 0.

[110] Shen C, Ding J, Wang Z, Cao D, Ding X, Hou T. From machine learning to deep learning: advances in scoring functions for protein-ligand docking. Wiley Interdiscip Rev Comput Mol Sci. 2020 Jan; 10 (1): e1429.

[111] Yasuo N, Sekijima M. Improved method of structure-based virtual screening via interaction-energy-based learning. J Chem Inf Model. 2019 Feb 26; 59 (3): 1050- 1061.

[112] Arora K, Bist AS. Artificial intelligence-based drug discovery techniques for covid-19 detection. Aptisi Transactions on Technopreneurship (ATT). 2020 Jun 16; 2 (2): 120- 126.

[113] Cereto-Massagué A, Ojeda MJ, Valls C, Mulero M, Garcia-Vallvé S, Pujadas G. Molecular fingerprint similarity search in virtual screening. Methods. 2015 Jan 1; 71: 58- 63.

[114] Muegge I, Mukherjee P. An overview of molecular fingerprint similarity search in virtual screening. Expet Opin Drug Discov. 2016 Feb 1; 11 (2): 137- 148.

[115] Khan A, Kaushik AC, Ali SS, Ahmad N, Wei DQ. Deep-learning-based target screening and similarity search for the predicted inhibitors of the pathways in Parkinson's disease. RSC advances. 2019; 9 (18): 10326- 10339.

[116] Maltarollo VG, Gertrudes JC, Oliveira PR, Honorio KM. Applying machine learning techniques for ADME-Tox prediction: a review. Expet Opin Drug Metabol Toxicol. 2015 Feb 1; 11 (2): 259- 271.

[117] Alqahtani S. In silico ADME-Tox modeling: progress and prospects. Expet Opin Drug Metabol Toxicol. 2017 Nov 2; 13 (11): 1147- 1158.

[118] Bácskay I, Nemes D, Fenyvesi F, et al. Role of cytotoxicity experiments in pharmaceutical development. Cytotoxicity. 2018 Jul 25; 8: 131- 146.

[119] Jimenez-Carretero D, Abrishami V, Fernandez-de-Manuel L, et al. Tox_ (R) CNN: deep learning-based nuclei profiling tool for drug toxicity screening. PLoS Comput Biol. 2018 Nov 30; 14 (11): e1006238.

[120] Djoumbou-Feunang Y, Fiamoncini J, Gil-de-la-Fuente A, Greiner R, Manach C, Wishart DS. BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification. J Cheminf. 2019 Dec; 11: 1- 25.

[121] Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Mol Divers. 2022 Jun; 26 (3): 1893- 1913.

[122] Wang D, Liu W, Shen Z, et al. Deep learning based drug metabolites prediction. Front Pharmacol. 2020 Jan 30; 10: 1586.

[123] Korshunova M, Ginsburg B, Tropsha A, Isayev O. OpenChem: a deep learning toolkit for computational chemistry and drug design. J Chem Inf Model. 2021 Jan 4; 61 (1): 7- 13.

[124] Sahoo P, Roy I, Wang Z, et al. MultiCon: a semi-supervised approach for predicting drug function from chemical structure analysis. J Chem Inf Model. 2020 Nov 3; 60 (12): 5995- 6006.

[125] Piantadosi S. Clinical Trials: A Methodologic Perspectiv. John Wiley & Sons; 2024 Apr 30.

[126] Friedman LM, Furberg C, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. New York: springer; 2010 Sep 21.

[127] Harrer S, Shah P, Hu J. Artificial intelligence for clinical trial design. Trends in pharmacological sciences. 2019 Aug 1; 40 (8): 577- 591.

[128] Walczak S. The role of artificial intelligence in clinical decision support systems and a classification framework. International Journal of Computers in Clinical Practice (IJCCP). 2018 Jul 1; 3 (2): 31- 47.

[129] Woo M. An AI boost for clinical trials. Nature. 2019 Sep 1; 573 (7775): S100.

[130] Nag S, Baidya ATK, Mandal A, et al. Deep learning tools for advancing drug discovery and development. 3 Biotech. 2022 May; 12 (5): 110.

[131] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021 Aug; 25 (3): 1315- 1360.

[132] Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020 Jan 1; 18: 784- 790.

[133] Scudellari M. Five companies using AI to fight coronavirus. IEEE Spectrum. 2020.

[134] Gatti M, Turrini E, Raschi E, Sestili P, Fimognari C. Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues. Pharmaceuticals. 2021 Jul 28; 14: 738.

[135] Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019- nCoV acute respiratory diseas. Lancet (London, England). 2020 Feb 15; 395 (10223): e30.

[136] Flaten HK, St Claire C, Schlager E, Dunnick CA, Dellavalle RP, et al. Growth of mobile applications in dermatology-2017 update. Dermatol Online J. 2018; 24 (2).

[137] de Carvalho TM, Noels E, Wakkee M, Udrea A, Nijsten T, et al. Development of smartphone apps for skin cancer risk assessment: progress and promise. JMIR Dermatology. 2019 Jul 11; 2 (1).

[138] Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke and vascular neurology. 2017 Dec 1; 2 (4).

[139] Manikiran SS, Prasanthi NL. Artificial intelligence: milestones and role in pharma and healthcare sector. Pharma times. 2019; 51: 9- 56.

RIGHTS & PERMISSIONS

The Authors. Publishing services by Elsevier B.V. on behalf of Higher Education Press and KeAi Communications Co. Ltd.